Cardiogenic potency of cardiac progenitors versus mesenchymal stromal cells

by Alexey Bersenev on February 14, 2012 · 1 comment

in other adult stem cells

Post to Twitter Send Gmail Post to LinkedIn

Therapeutic use of cardiac progenitor/ stem cells is a hot topic today. The results of CADUCEUS trial were just released. The senior author of this study – Eduardo Marban has recently mentioned:

In head-to-head comparison study, cardiosphere-derived cells were superior to bone marrow-derived mesenchymal stem cells.

A new study, published in Stem Cells translational Medicine, evaluated the potency of human cardiac stem cells (CSCs) versus mesenchymal stromal cells (MSCs):

We hypothesized that human CSCs have greater ability than MSCs to engraft, differentiate, and improve cardiac function. We compared intramyocardial injection of human fetal CSCs (36,000) with two doses of adult MSCs (36,000 and 1,000,000) or control (phosphate buffered saline) in nonobese diabetic/severe combined immune deficiency mice after coronary artery ligation.

As one may predict, in order to reach the same potency tissue-derived stem cells (for homologous use) could require much less number of cells than bone marrow populations due to higher specificity:

MSCs required a 30-fold greater dose than CSCs to improve cardiac function and anatomy. Together, these findings demonstrate a greater potency of CSCs than bone marrow MSCs in cardiac repair.

{ 1 comment… read it below or add one }

Owen Bain February 15, 2012 at 2:13 pm

In the Oskouei et al study MSCs used were thawed prior to injection, unlike the CSCs that were ‘fresh’ and just resuspended in PBS. Would have been a great study if they were completely comparable instead of having this variable. All the same was interesting to see huge differences between no of cells engrafted (30 to 0.7/mm2 CSCs vs MSCs)


Leave a Comment

Previous post:

Next post: